Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.

Science 19 August 1983:
Vol. 221. no. 4612, pp. 719 - 725
DOI: 10.1126/science.6192498
Prev | Table of Contents | Next

Articles

Science, Vol 221, Issue 4612, 719-725
Copyright © 1983 by American Association for the Advancement of Science

articles

Angiogenesis inhibition and tumor regression caused by heparin or a heparin fragment in the presence of cortisone

J Folkman, R Langer, RJ Linhardt, C Haudenschild, and S Taylor

Heparin or a heparin fragment administered with cortisone inhibited angiogenesis, caused regression of large tumor masses, and prevented metastases. Oral administration of heparin resulted in the release of non-anticoagulant heparin fragments in the serum which, in the presence of cortisone, had similar anti-angiogenic and antitumor effects. Of all the heparin fragments tested, the most potent inhibition of angiogenesis in the presence of cortisone was provided by a hexasaccharide with a molecular weight of about 1600.


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
Impact of Venous Thromboembolism and Anticoagulation on Cancer and Cancer Survival.
N. M. Kuderer, T. L. Ortel, and C. W. Francis (2009)
J. Clin. Oncol. 27, 4902-4911
   Abstract »    Full Text »    PDF »
Low-molecular-weight heparin in cancer-associated thrombosis: treatment, secondary prevention, and survival.
J. Nishioka and S. Goodin (2007)
Journal of Oncology Pharmacy Practice 13, 85-97
   Abstract »    PDF »
Low-Molecular-Weight Heparin in Patients With Advanced Cancer: A Phase 3 Clinical Trial.
K. Sideras, P. L. Schaefer, S. H. Okuno, J. A. Sloan, L. Kutteh, T. R. Fitch, S. R. Dakhil, R. Levitt, S. R. Alberts, R. F. Morton, et al. (2006)
Mayo Clin. Proc. 81, 758-767
   Abstract »    Full Text »    PDF »
Heparin Octasaccharides Inhibit Angiogenesis In vivo.
J. Hasan, S. D. Shnyder, A. R. Clamp, A. T. McGown, R. Bicknell, M. Presta, M. Bibby, J. Double, S. Craig, D. Leeming, et al. (2005)
Clin. Cancer Res. 11, 8172-8179
   Abstract »    Full Text »    PDF »
Preventing local regeneration of glucocorticoids by 11{beta}-hydroxysteroid dehydrogenase type 1 enhances angiogenesis.
G. R. Small, P. W. F. Hadoke, I. Sharif, A. R. Dover, D. Armour, C. J. Kenyon, G. A. Gray, and B. R. Walker (2005)
PNAS 102, 12165-12170
   Abstract »    Full Text »    PDF »
Inhibition of Angiogenesis: Thalidomide or Low-Molecular-Weight Heparin?.
M. Ozkan, B. Eser, O. Er, G. G. Dogu, and M. Altinbas (2005)
J. Clin. Oncol. 23, 2113
   Full Text »    PDF »
Antiangiogenic Steroids in Human Cancer Therapy.
R. J. Pietras and O. K. Weinberg (2005)
Evid. Based Complement. Altern. Med. 2, 49-57
   Abstract »    Full Text »    PDF »
Isolation and characterization of a heparin with high anticoagulant activity from the clam Tapes phylippinarum: evidence for the presence of a high content of antithrombin III binding site.
M. Cesaretti, E. Luppi, F. Maccari, and N. Volpi (2004)
Glycobiology 14, 1275-1284
   Abstract »    Full Text »    PDF »
The heparins and cancer: review of clinical trials and biological properties.
R. Castelli, F. Porro, and P. Tarsia (2004)
Vascular Medicine 9, 205-213
   Abstract »    PDF »
Heparin and Angiogenesis: Size Matters!.
J. Rak and J. I. Weitz (2003)
Arterioscler Thromb Vasc Biol 23, 1954-1955
   Full Text »    PDF »
Heparin Inhibition of Endothelial Cell Proliferation and Organization Is Dependent on Molecular Weight.
A. A. Khorana, A. Sahni, O. D. Altland, and C. W. Francis (2003)
Arterioscler Thromb Vasc Biol 23, 2110-2115
   Abstract »    Full Text »    PDF »
Antiangiogenic effects of dexamethasone in 9L gliosarcoma assessed by MRI cerebral blood volume maps.
M. A. Badruddoja, H. G.J. Krouwer, S. D. Rand, K. J. Rebro, A. P. Pathak, and K. M. Schmainda (2003)
Neuro-oncol 5, 235-243
   Abstract »    PDF »
The Complex Effects of Heparins on Cancer Progression and Metastasis in Experimental Studies.
S. M. Smorenburg and C. J. F. Van Noorden (2001)
Pharmacol. Rev. 53, 93-106
   Abstract »    Full Text »    PDF »
Anti-Kaposi's Sarcoma and Antiangiogenic Activities of Sulfated Dextrins.
M. Thornton, L. Barkley, J. C. Mason, and S. Shaunak (1999)
Antimicrob. Agents Chemother. 43, 2528-2533
   Abstract »    Full Text »
Identification of Sulfated Oligosaccharide-based Inhibitors of Tumor Growth and Metastasis Using Novel in Vitro Assays for Angiogenesis and Heparanase Activity.
C. R. Parish, C. Freeman, K. J. Brown, D. J. Francis, and W. B. Cowden (1999)
Cancer Res. 59, 3433-3441
   Abstract »    Full Text »    PDF »
Carboxymethyl Benzylamide Dextran Blocks Angiogenesis of MDA-MB435 Breast Carcinoma Xenografted in Fat Pad and Its Lung Metastases in Nude Mice.
R. Bagheri-Yarmand, Y. Kourbali, A. M. Rath, R. Vassy, A. Martin, J. Jozefonvicz, C. Soria, H. Lu, and M. Crepin (1999)
Cancer Res. 59, 507-510
   Abstract »    Full Text »    PDF »
Low-Molecular-Weight Heparin Therapy and Mortality.
K. A. Valentine, R. D. Hull, and G. F. Pineo (1998)
Perspectives in Vascular Surgery and Endovascular Therapy 9, 99-108
   Abstract »    PDF »
Reduction in Thrombotic Events With Heparin-Coated Palmaz-Schatz Stents in Normal Porcine Coronary Arteries.
P. A. Hardhammar, H. M.M. van Beusekom, H. U. Emanuelsson, S. H. Hofma, P. A. Albertsson, P. D. Verdouw, E. Boersma, P. W. Serruys, and W. J. van der Giessen (1996)
Circulation 93, 423-430
   Abstract »    Full Text »
Orally Ingested Heparin Is Absorbed in, Humans.
H. Engelberg (1995)
Clinical and Applied Thrombosis/Hemostasis 1, 283-285
   Abstract »    PDF »
Systemic Antiangiogenic Therapy for Choroidal Neovascularization: What Is the Role of Interferon Alfa?.
D. R. Guyer, A. P. Adamis, E. S. Gragoudas, J. Folkman, J. S. Slakter, and L. A. Yannuzzi (1992)
Arch Ophthalmol 110, 1383-1384
   Abstract »    PDF »
Review : Synthetic Polymers with Intrinsic Anticancer Activity.
L. Seymour (1991)
Journal of Bioactive and Compatible Polymers 6, 178-216
   PDF »
Identification of an inhibitor of neovascularization from cartilage.
M. Moses, J Sudhalter, and R Langer (1990)
Science 248, 1408-1410
   Abstract »    PDF »
Control of angiogenesis with synthetic heparin substitutes.
J Folkman, P. Weisz, M. Joullie, W. Li, and W. Ewing (1989)
Science 243, 1490-1493
   Abstract »    PDF »
Extracellular Modulating Factors and the Control of Intraocular Neovascularization: An Overview.
B. M. Glaser (1988)
Arch Ophthalmol 106, 603-607
   Abstract »    PDF »
Angiogenic factors.
J Folkman and M Klagsbrun (1987)
Science 235, 442-447
   Abstract »    PDF »
A new class of steroids inhibits angiogenesis in the presence of heparin or a heparin fragment.
R Crum, S Szabo, and J Folkman (1985)
Science 230, 1375-1378
   Abstract »    PDF »
Lipid Angiogenic Factor From Omentum.
H. S. Goldsmith, A. L. Griffith, A. Kupferman, and N. Catsimpoolas (1984)
JAMA 252, 2034-2036
   Abstract »    PDF »
Heparin binds endothelial cell growth factor, the principal endothelial cell mitogen in bovine brain.
T Maciag, T Mehlman, R Friesel, and A. Schreiber (1984)
Science 225, 932-935
   Abstract »    PDF »
Heparin affinity: purification of a tumor-derived capillary endothelial cell growth factor.
Y Shing, J Folkman, R Sullivan, C Butterfield, J Murray, and M Klagsbrun (1984)
Science 223, 1296-1299
   Abstract »    PDF »
Activation of EphB2 and Its Ligands Promotes Vascular Smooth Muscle Cell Proliferation.
T. C. Woods, C. R. Blystone, J. Yoo, and E. R. Edelman (2002)
J. Biol. Chem. 277, 1924-1927
   Abstract »    Full Text »    PDF »
Mechanisms of normal and tumor-derived angiogenesis.
M. Papetti and I. M. Herman (2002)
Am J Physiol Cell Physiol 282, C947-C970
   Abstract »    Full Text »    PDF »


To Advertise     Find Products

Science. ISSN 0036-8075 (print), 1095-9203 (online)